Skip to content

Biofilm Formation and Antifungal Resistance in Candida Species

Biofilm Formation and Antifungal Resistance in Candida Species: A Comparative Study of Albicans and Non Albicans Strains in Hematology ICU.

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07245563
Enrollment
300
Registered
2025-11-24
Start date
2025-12-20
Completion date
2026-10-12
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Candida Infection

Brief summary

1. To determine the susceptibility pattern of our local isolated Candida strains which is essential for optimal management of fungal infection. 2. Detection of biofilm formation by conventional and molecular methods 3. Comparison between C. albicans and non-albicans in the prevalence of biofilm formation and biofilm -forming genes 4. Find the association between antifungal resistance and biofilm formation in candida strains isolated from patients 5. Determination of clinical factors associated with occurrence of infections.

Detailed description

Candida spp are the fourth cause of nosocomial blood stream infections and had a 37% mortality rate within 30-day duration. Early diagnosis of Candida invasive infections reduces the mortality rate from 40% to 15% after therapy .There are several Candida species such as Candida albicans , Candida glabrata but C. albicans remains the most frequent species isolated there is an ongoing shift from C. albicans to non-albicans. Was reported by several countries. C. albicans, C. tropicalis, C. parapsilosis,C. krusei and C. glabrata are responsible for over 90% of cases of candidal infection .Several pathogenic virulence factors are encoded by C. albicans genes and assist the fungus to invade the host tissues leading to infections as the capacity of C. albicans to change from the budding yeast form to filamentous form .Many microbes, including yeasts, form biofilms as one of the major virulence factors. Candida infections often get therapeutic failure, mostly as a result of antifungal resistance that is caused by several mechanisms including biofilm production as biofilm- producing strains show significant increased resistance to antifungal drugs and host immunity. Candida auris is an emergent pathogen that was first described in Japan. C. auris can be challenging to identify in the laboratory using conventional. Importantly, C. auris isolates are resistant to fluconazole and frequently show multidrug resistance.C. auris has a high capacity for dissemination via contaminated surfaces or horizontal patient-to-patient transfer, which is unusual in other Candida species.

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Eligible participants in the study were those with invasive infection and had one or more of this criteria : oSuppressed general body immunity. oSuppressed local body immunity as a result of trauma or invasive procedures. oResistant to antibiotic therapy. oNegative samples for bacterial examination and culture. Critical life threatening infect

Exclusion criteria

* Patients who received antifungal therapy within 3 days prior to sample collection. * Resistant to antibiotic therapy.

Design outcomes

Primary

MeasureTime frame
To asses the prevalence of candida species as a cause of infection in patient in hematology intinsive care unit1 year
To asses the prevalence of genes responsible for biofilm formation in different candida species1 year

Contacts

Primary Contactmennat-allah khaled abdelhady
roserena2@gmail.com00201151387078

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026